Company Overview of XenoBiosis International B.V.
XenoBiosis International B.V. develops and produces biological substances and compounds. It offers Ginkgo Terp, an extract of the Ginkgo biloba tree for dietary supplements, skin creams, and pharmaceutical compositions; Bilobalide as an ingredient; and Gingko A + B compounds for cardiovascular, atherosclerosis, and erectile dysfunction applications. The company’s products are also used to treat Alzheimer’s disease, Parkinson’s disease, mood/anxiety, cancer progression, cognitive function, and neuronal damage. XenoBiosis International was founded in 2000 and is based in Lelystad, the Netherlands.
Lelystad, 8211 AR
Founded in 2000
31 320 286 333
31 320 286 986
Key Executives for XenoBiosis International B.V.
Similar Private Companies By Industry
|All-Gen Pharmaceuticals and Generics B.V.||Europe|
|Alzheimer Research Centrum BV||Europe|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
|The Advertising Council, Inc.||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact XenoBiosis International B.V., please visit www.xenobiosis.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.